Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2013 by Clarus Therapeutics, Inc..
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Clarus Therapeutics, Inc. Identifier:
First received: September 5, 2012
Last updated: December 17, 2013
Last verified: December 2013
The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.

Condition Intervention Phase
Male Hypogonadism
Drug: Oral testosterone undecanoate
Drug: Transdermal testosterone gel (AndroGel)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Resource links provided by NLM:

Further study details as provided by Clarus Therapeutics, Inc.:

Primary Outcome Measures:
  • Evidence of clinically significant safety related events in each treatment group [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Clinical laboratory, prostate volume, and cardiovascular biomarkers

Enrollment: 182
Study Start Date: August 2012
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral testosterone undecanoate
Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
Drug: Oral testosterone undecanoate
Active Comparator: Transdermal testosterone gel (AndroGel)
Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
Drug: Transdermal testosterone gel (AndroGel)


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Successful completion of CLAR-09007
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01699178

  Show 30 Study Locations
Sponsors and Collaborators
Clarus Therapeutics, Inc.
Principal Investigator: Ronald Swerdloff, MD University of California, Los Angeles
  More Information

Responsible Party: Clarus Therapeutics, Inc. Identifier: NCT01699178     History of Changes
Other Study ID Numbers: CLAR-12010 
Study First Received: September 5, 2012
Last Updated: December 17, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on October 21, 2016